These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36162852)

  • 1. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
    Yang X; Eriksson M; Czene K; Lee A; Leslie G; Lush M; Wang J; Dennis J; Dorling L; Carvalho S; Mavaddat N; Simard J; Schmidt MK; Easton DF; Hall P; Antoniou AC
    J Med Genet; 2022 Dec; 59(12):1196-1205. PubMed ID: 36162852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
    Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
    Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on
    Lee A; Mavaddat N; Cunningham A; Carver T; Ficorella L; Archer S; Walter FM; Tischkowitz M; Roberts J; Usher-Smith J; Simard J; Schmidt MK; Devilee P; Zadnik V; Jürgens H; Mouret-Fourme E; De Pauw A; Rookus M; Mooij TM; Pharoah PP; Easton DF; Antoniou AC
    J Med Genet; 2022 Dec; 59(12):1206-1218. PubMed ID: 36162851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 10-year performance of four models of breast cancer risk: a validation study.
    Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
    Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the BOADICEA model in a prospective cohort of
    Yang X; Mooij TM; Leslie G; Ficorella L; Andrieu N; Kast K; Singer CF; Jakubowska A; van Gils CH; Tan YY; Engel C; Adank MA; van Asperen CJ; Ausems MGEM; Berthet P; ; Collee MJ; Cook JA; Eason J; Spaendonck-Zwarts KYV; Evans DG; Gómez García EB; Hanson H; Izatt L; Kemp Z; Lalloo F; Lasset C; Lesueur F; Musgrave H; Nambot S; Noguès C; Oosterwijk JC; Stoppa-Lyonnet D; Tischkowitz M; Tripathi V; Wevers MR; Zhao E; van Leeuwen FE; Schmidt MK; Easton DF; Rookus MA; Antoniou AC
    J Med Genet; 2024 Jul; 61(8):803-809. PubMed ID: 38834293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.
    Yang X; Wu Y; Ficorella L; Wilcox N; Dennis J; Tyrer J; Carver T; Pashayan N; Tischkowitz M; Pharoah PDP; Easton DF; Antoniou AC
    Br J Cancer; 2024 Nov; 131(9):1473-1479. PubMed ID: 39294438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.
    Møller NB; Boonen DS; Feldner ES; Hao Q; Larsen M; Lænkholm AV; Borg Å; Kvist A; Törngren T; Jensen UB; Boonen SE; Thomassen M; Terkelsen T
    Sci Rep; 2023 May; 13(1):8536. PubMed ID: 37237042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
    Lee A; Mavaddat N; Wilcox AN; Cunningham AP; Carver T; Hartley S; Babb de Villiers C; Izquierdo A; Simard J; Schmidt MK; Walter FM; Chatterjee N; Garcia-Closas M; Tischkowitz M; Pharoah P; Easton DF; Antoniou AC
    Genet Med; 2019 Aug; 21(8):1708-1718. PubMed ID: 30643217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
    Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
    J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
    MacInnis RJ; Bickerstaffe A; Apicella C; Dite GS; Dowty JG; Aujard K; Phillips KA; Weideman P; Lee A; Terry MB; Giles GG; Southey MC; Antoniou AC; Hopper JL
    Br J Cancer; 2013 Sep; 109(5):1296-301. PubMed ID: 23942072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
    Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort.
    Lakeman IMM; Rodríguez-Girondo M; Lee A; Ruiter R; Stricker BH; Wijnant SRA; Kavousi M; Antoniou AC; Schmidt MK; Uitterlinden AG; van Rooij J; Devilee P
    Genet Med; 2020 Nov; 22(11):1803-1811. PubMed ID: 32624571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
    Ståhlbom AK; Johansson H; Liljegren A; von Wachenfeldt A; Arver B
    Fam Cancer; 2012 Mar; 11(1):33-40. PubMed ID: 22124624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
    Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
    Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
    Antoniou AC; Cunningham AP; Peto J; Evans DG; Lalloo F; Narod SA; Risch HA; Eyfjord JE; Hopper JL; Southey MC; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tryggvadottir L; Syrjakoski K; Kallioniemi OP; Eerola H; Nevanlinna H; Pharoah PD; Easton DF
    Br J Cancer; 2008 Apr; 98(8):1457-66. PubMed ID: 18349832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
    Antoniou AC; Pharoah PP; Smith P; Easton DF
    Br J Cancer; 2004 Oct; 91(8):1580-90. PubMed ID: 15381934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks.
    Wolfson M; Gribble S; Pashayan N; Easton DF; Antoniou AC; Lee A; van Katwyk S; Simard J
    Genet Med; 2021 Nov; 23(11):2114-2121. PubMed ID: 34230637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
    Evans DG; Brentnall A; Byers H; Harkness E; Stavrinos P; Howell A; ; Newman WG; Cuzick J
    J Med Genet; 2017 Feb; 54(2):111-113. PubMed ID: 27794048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.